Sign In
Buy AVRO
$1.40
+0 (+0%)
At Close: Sep 19, 2024
AVROBIO to Participate in Upcoming April Investor Conferences
11:00am, Thursday, 26'th Mar 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Wednesday, 25'th Mar 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory
AVROBIO, Inc.(AVRO) Getting Un-Liked By Institutional Investors? | Post Analyst
12:03pm, Friday, 20'th Mar 2020
Analysts have clear opinions on AVRO. There are 4 analysts on the Wall offering 12 month price targets for Avrobio in the last 3 months. The average price target is $40.00 with a high forecast of $50.
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
11:36am, Wednesday, 18'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron P
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.
AVRO LOSS NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Announces Investigation of Securities Claims Against AVROBIO, Inc. – AVRO
05:57pm, Tuesday, 17'th Mar 2020
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO), resulting from allegations that
AVRO Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AVROBIO, Inc. and Encourages Investors to Contact the Firm
04:25pm, Tuesday, 17'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 17, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AVROBIO, Inc. ("AVROBIO" or the Company") (NASDAQ:AVRO).Inv
Avrobio (AVRO) Gets a Buy Rating from Mizuho Securities
08:16am, Tuesday, 17'th Mar 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO) today and set a price target of $35.00. The company's shares closed last
Avrobio (AVRO) Gets a Buy Rating from Mizuho Securities
08:16am, Tuesday, 17'th Mar 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price
AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
11:00am, Monday, 16'th Mar 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter an
AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
11:00am, Monday, 09'th Mar 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration
NTAP, AEG among premarket losers
02:17pm, Thursday, 13'th Feb 2020
XBiotech (NASDAQ:XBIT) -26% on preliminary results of tender offer.Akorn (NASDAQ:AKRX) -20% after extending standstill period.Catalyst Biosciences (NASDAQ:CBIO) -18% on equity offering.Nu Skin En
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
01:05pm, Thursday, 13'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (N
